Insitro - vitro models of human disease
Insitro
Headquarters: South San Francisco
Founders: Daphne Koller (CEO)
Funding: $100 million
Valuation: $135 million, via Pitchbook
Insitro aims to improve the drug discovery process. Founded by machine-learning veteran Daphne Koller, it creates in vitro models of human disease in its automated laboratory and then applies machine-learning models to predict possible effective therapies. It recently announced a partnership with drug maker Gilead Sciences, worth up to $1 billion, to help it find a treatment for a form of liver disease called nonalcoholic steatohepatis, or NASH.
Comments
Post a Comment